- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02195154
18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism
18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism: Investigating the Correlation Between Cerebral Structural and Functional Changes, and Clinical Manifestation
Study Overview
Detailed Description
Study duration is expected to be completed in a period of 3 year. The study will enroll 40 patients with VP and 20 healthy subjects.
This neuroimaging study includes the 18F-FP-(+)-DTBZ PET, MRI structure images, diffusion tensor imaging, susceptibility weighted imaging, resting state and gait-related imagery task functional MRI. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject group, each subject will have 3 visits in this study. Safety measurement for 18F-FP-(+)-DTBZ will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Taoyuan, Taiwan, 333
- Chang Gung Memory Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Forty patients with a diagnosis of VP whom must: i. Male or female patients; age range 45~80 years old. ii. Written and dated informed consent by self or by legal representative, to be obtained before any of the study procedures.
iii. Patients should be fulfilled the diagnostic criteria of vascular parkinsonism (Appendix I).
2. Twenty healthy subjects whom must: i. Male or female patients; age range 45~80 years old. ii. Written and dated informed consent by self or by legal representative, to be obtained before any of the study procedures.
Exclusion Criteria:
- Pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the PI discretion) or current breast feeding.
Any subject who has a clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness.
I. Clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances.
II. Current clinically significant cardiovascular disease. (cardiac surgery or myocardial infarction within the last 6 months; unstable angina; decompensated congestive heart failure; significant cardiac arrhythmia; congenital heart disease.)
- History of drug or alcohol abuse within the last year, or prior prolonged history of abuse.
- History or presence of QTc prolongation.
- History of intracranial operation, including thalamotomy, pallidotomy, and/or deep brain stimulation.
- History of repeated head injury, hydrocephalus, encephalitis or cerebral tumors.
- History of neurotoxin exposure
- Any documented abnormality in the brain by CT or MRI of brain, which might contribute to the motor function, such as hydrocephalus or encephalomalacia, will be excluded. Cerebral vascular lesions are allowed for VP patients. Mild cortical atrophy will be allowed for all subjects.
- Patients who have neurodegenerative diseases, such as spinocerellar atrophy (SCA), Wilson's disease, Parkinson's disease or Parkinson plus syndrome, are excluded.
- General PET exclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 18F-DTBZ for Vascular Parkinsonism
This neuroimaging study includes the 18F-FP-(+)-DTBZ PET, MRI structure images, diffusion tensor imaging, susceptibility weighted imaging, resting state and gait-related imagery task functional MRI.
Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject group, each subject will have 3 visits in this study.
Safety measurement for 18F-FP-(+)-DTBZ will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
|
During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging. The compound is labeled with fluorine 18F that decays by positron (β+) emission and has a half life of 109.7 min. The principal photons useful for diagnostic imaging are the 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron. The proposed dose for this study is based on the phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The difference of specific uptake ratio (SUR) of 18F-DTBZ between disease and control group
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The correlation between parameters from different imaging modalities and the severity of motor symptoms or cognition in disease group.
Time Frame: 3 years
|
The neuroimaging parameters include the SURs of 18F-DTBZ in each brain regions, diffusion indices in each brain regions, MARS score, and activated voxels in each brain regions from the gait-related imagery task functional MRI.
|
3 years
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The difference of diffusion indices obtained from DTI between disease and control group
Time Frame: 3 years
|
3 years
|
The difference of microbleed anatomical rating scale (MARS) score obtained from the SWI between disease and control group.
Time Frame: 3 years
|
3 years
|
The difference of functional connectivity maps associated with the seed region of interest (resting state functional MRI) between disease and control group.
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 101-4624A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vascular Parkinsonism
-
Inje UniversityDongtan Sacred Heart HospitalNot yet recruiting
-
Ain Shams UniversityCompletedParkinson's Disease | Vascular ParkinsonismEgypt
-
Amsterdam UMC, location VUmcParkinsonverenigingUnknownParkinsonism, Experimental | Parkinsonism, Treatment as UsualNetherlands
-
University of RochesterUniversity of Colorado, Denver; Massachusetts General Hospital; Stanford UniversityRecruitingParkinson Disease | Multiple System Atrophy | Corticobasal Degeneration | Progressive Supranuclear Palsy | Parkinson's Disease and Parkinsonism | Dementia With Lewy Bodies | Vascular Parkinsonism | Parkinson Disease Dementia | Lewy Body ParkinsonismUnited States
-
Queen Mary University of LondonNot yet recruitingDystonia | Multiple System Atrophy | Corticobasal Degeneration | Progressive Supranuclear Palsy | Tremor | Parkinson's Disease and Parkinsonism | Vascular Parkinsonism
-
Maastricht University Medical CenterFunding: Stichting Internationaal Parkinson Fonds, The NetherlandsCompletedParkinson's Disease | Supranuclear Palsy, Progressive | Multiple System Atrophy | Essential Tremor | Vascular Parkinsonism | Parkinsonian Syndrome | Drug Induced ParkinsonismNetherlands
-
Chang Gung Memorial HospitalUnknownCarbon Monoxide-induced ParkinsonismTaiwan
-
Ceraxis Health, IncRecruitingMovement Disorders (Incl Parkinsonism)United States
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Azienda Socio Sanitaria Territoriale Nord MilanoActive, not recruitingParkinson Disease | Nurse-Patient Relations | Atypical Parkinsonism | Nurse Physician Relations | Secondary ParkinsonismItaly
-
California Pacific Medical Center Research InstituteUniversity of Pittsburgh; Duke University; National Institute on Aging (NIA); University... and other collaboratorsRecruitingParkinson Disease | Osteoporosis | Parkinsonism | Multiple System Atrophy | Progressive Supranuclear Palsy | Parkinson's Disease and Parkinsonism | Dementia With Lewy Bodies | Atypical Parkinsonism | Vascular ParkinsonismUnited States
Clinical Trials on 18F-DTBZ
-
Chang Gung Memorial HospitalCompleted
-
Chang Gung Memorial HospitalCompleted
-
Chang Gung Memorial HospitalNational Science Council, TaiwanCompleted
-
Chang Gung Memorial HospitalCompletedParkinson's DiseaseTaiwan
-
Chang Gung Memorial HospitalNational Science Council, TaiwanCompletedParkinson's DiseaseTaiwan
-
Chang Gung Memorial HospitalCompleted
-
Chang Gung Memorial HospitalUnknownCarbon Monoxide-induced ParkinsonismTaiwan
-
Yale UniversityPfizer; Avid RadiopharmaceuticalsCompletedDiabetes Mellitus, Type 1United States
-
Centre for Addiction and Mental HealthRecruitingMajor Depressive Disorder | Long COVID | Major Depressive EpisodeCanada
-
Columbia UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)WithdrawnDiabetes Mellitus, Type 1 | Healthy VolunteersUnited States